Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Yohimbine

Yohimbine (Pausinystalia johimbe bark alkaloid)

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Supplement form unregulated; prescription yohimbine HCl exists separately

Reference only. Not medical advice.

What can go wrong

Can cause anxiety, panic attacks, tachycardia, hypertension, insomnia, and, at higher doses, dangerous cardiovascular events. Hazardous with MAO inhibitors, certain antidepressants, stimulants, and in people with cardiovascular disease, anxiety disorders, or hypertension. Supplement-grade products have unreliable dosing. Not a testosterone booster.

This is something to take to a clinician. The Atlas can tell you what is known about yohimbine in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

An alkaloid from yohimbe bark that acts as an alpha-2 adrenergic receptor antagonist. It is a genuinely active pharmacological agent (a prescription form, yohimbine HCl, has been used for erectile dysfunction) sold over the counter as a supplement, where bark-extract products are notoriously inconsistent in actual yohimbine content. It is relevant to erectile function and fat loss rather than to raising testosterone, and it carries meaningful cardiovascular and psychiatric risk.

A real alpha-2 antagonist drug sold as a supplement, with real cardiovascular risk.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Erectile function (modest, mechanism-based)
  • Fat-loss aid
  • Sexual dysfunction (including some SSRI-induced cases)
  • Pre-workout stimulation

How it is supposed to work

By blocking alpha-2 adrenergic receptors, yohimbine increases sympathetic outflow and noradrenaline release, which can enhance penile blood flow and mobilize fat from adipose tissue. It is not a testosterone-raising agent; its inclusion in 'testosterone' marketing is mismatched to its mechanism.

A drug, not a benign booster

Yohimbine is pharmacologically active with a narrow comfort margin: it can raise heart rate and blood pressure, trigger anxiety and panic, and interact with antidepressants and blood-pressure medication. Bark-extract supplements often contain wildly variable, sometimes dangerous, amounts of actual yohimbine, making accidental overdose a real risk.

What people get wrong

  • Often saidYohimbine raises testosterone

    ActuallyNo. It is an alpha-2 antagonist relevant to blood flow and fat loss, not an androgen modulator.

  • Often saidNatural yohimbe bark is a mild supplement

    ActuallyIt contains an active drug with real cardiovascular risk and notoriously inconsistent dosing.

Who profits, and who pushes back

  • Supplement-quality researchers

    Pushes backAnalytical pharmacology

    Independent testing has repeatedly found yohimbe supplements with actual yohimbine content far different from the label, a genuine safety hazard for an active cardiovascular drug.

  • Fat-loss and pre-workout marketers

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itModerate

    Promoted mainly for fat loss and stimulation; cardiovascular cautions often understated

How we got here

Yohimbe bark has been used traditionally in West/Central Africa as an aphrodisiac. The isolated alkaloid yohimbine was studied medically and became a prescription treatment for erectile dysfunction before PDE5 inhibitors largely displaced it. The over-the-counter bark-extract supplement market grew separately, with major quality-control problems.

  1. TraditionalWest/Central African aphrodisiac use
  2. 20th c.Yohimbine HCl developed as a prescription ED treatment
  3. 1998+Largely displaced for ED by PDE5 inhibitors
  4. OngoingOTC bark extracts persist with inconsistent dosing

At a glance

Source
Yohimbe bark (Pausinystalia johimbe)
Mechanism
Alpha-2 adrenergic antagonist
Best-supported angle
Erectile function (modest), fat loss
Key risk
Cardiovascular and anxiety effects

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Yohimbine. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Yohimbine HCl ED trials (summary)various

    Prescription yohimbine showed modest benefit over placebo for erectile dysfunction, particularly non-organic ED; effect sizes are limited